Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

U.S. Should Revamp Dialysis Drug Payments, Auditor Says

March 25 (Bloomberg) -- Dialysis centers run by DaVita HealthCare Partners, Fresenius Medical Care and other cos aren’t being paid correctly by the Medicare program because the U.S. is miscalculating drug costs, govt auditors said. * Report to be released today by the HHS’s Office of Inspector

General recommended the agency that runs Medicare

recalculate payments to dialysis centers “to reflect

current trends in drug acquisition costs” * Prices paid by dialysis centers for Amgen’s Epogen, the most

expensive drug they use, increased at least 17% from 2009 to

2012, according to the report; prices for other drugs fell,

often by more than Medicare estimated * Report doesn’t say how payment should be recalculated or

whether it should be reduced * Story link: NSN N2YRWZ6K50YM <GO>

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

To contact the reporter on this story: Alex Wayne in Washington at +1-202-654-4339 or awayne3@bloomberg.net To contact the editors responsible for this story: Reg Gale at +1-212-617-2563 or rgale5@bloomberg.net Shiyin Chen

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.